Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jul 22;64(3):396–402. doi: 10.1136/ard.2003.019711

Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis

A Boonen 1, R van den Heuvel 1, A van Tubergen 1, M Goossens 1, J Severens 1, D van der Heijde 1, S van der Linden 1
PMCID: PMC1755408  PMID: 15271773

Abstract

Objective: To compare the cost of illness of three musculoskeletal conditions in relation to general wellbeing.

Methods: Patients with fibromyalgia, chronic low back pain (CLBP), and ankylosing spondylitis who were referred to a specialist and participated in three randomised trials completed a cost diary for the duration of the study, comprising direct medical and non-medical resource utilisation and inability to perform paid and unpaid work. Patients rated perceived wellbeing (0–100) at baseline. Univariate differences in costs between the groups were estimated by bootstrapping. Regression analyses assessed which variables, in addition to the condition, contributed to costs and wellbeing.

Results: 70 patients with fibromyalgia, 110 with chronic low back pain, and 111 with ankylosing spondylitis provided data for the cost analyses. Average annual disease related total societal costs per patient were €7813 for fibromyalgia, €8533 for CLBP, and €3205 for ankylosing spondylitis. Total costs were higher for fibromyalgia and CLBP than for ankylosing spondylitis, mainly because of cost of formal and informal care, aids and adaptations, and work days lost. Wellbeing was lower in fibromyalgia (mean, 48) and low back pain (mean, 42) than in ankylosing spondylitis (mean, 67). No variables other than diagnostic group contributed to differences in costs or wellbeing.

Conclusions: In patients under the care of a specialist, there were marked differences in costs and wellbeing between those with fibromyalgia or CLBP and those with ankylosing spondylitis. In particular, direct non-medical costs and productivity costs were higher in fibromyalgia and CLBP.

Full Text

The Full Text of this article is available as a PDF (98.7 KB).

Figure 1.

Figure 1

 Cox probability curve illustrating the proportion of patients incurring more than a specific amount of costs in €/patient per year for each of the three chronic back conditions. AS, ankylosing spondylitis; CLBP, chronic low back pain; FM, fibromyalgia.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker C., Rutten M., van Doorslaer E., Bennett K., van der Linden S. Feasibility of utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. J Rheumatol. 1994 Feb;21(2):269–274. [PubMed] [Google Scholar]
  2. Boonen A., van der Heijde D., Landewé R., Guillemin F., Rutten-van Mölken M., Dougados M., Mielants H., de Vlam K., van der Tempel H., Boesen S. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis. 2003 Aug;62(8):732–740. doi: 10.1136/ard.62.8.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boonen A., van der Heijde D., Landewé R., Spoorenberg A., Schouten H., Rutten-van Mölken M., Guillemin F., Dougados M., Mielants H., de Vlam K. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002 May;61(5):429–437. doi: 10.1136/ard.61.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goossens M. E., Rutten-Van Mölken M. P., Kole-Snijders A. M., Vlaeyen J. W., Van Breukelen G., Leidl R. Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. Health Econ. 1998 Feb;7(1):39–51. doi: 10.1002/(sici)1099-1050(199802)7:1<39::aid-hec323>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  5. Goossens M. E., Rutten-van Mölken M. P., Leidl R. M., Bos S. G., Vlaeyen J. W., Teeken-Gruben N. J. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. J Rheumatol. 1996 Jul;23(7):1246–1254. [PubMed] [Google Scholar]
  6. Goossens M. E., Rutten-van Mölken M. P., Vlaeyen J. W., van der Linden S. M. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000 Jul;53(7):688–695. doi: 10.1016/s0895-4356(99)00177-8. [DOI] [PubMed] [Google Scholar]
  7. Hidding A., van Santen M., De Klerk E., Gielen X., Boers M., Geenen R., Vlaeyen J., Kester A., van der Linden S. Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. J Rheumatol. 1994 May;21(5):818–823. [PubMed] [Google Scholar]
  8. Picavet H. S. J., Schouten J. S. A. G. Musculoskeletal pain in the Netherlands: prevalences, consequences and risk groups, the DMC(3)-study. Pain. 2003 Mar;102(1-2):167–178. doi: 10.1016/s0304-3959(02)00372-x. [DOI] [PubMed] [Google Scholar]
  9. Robinson Rebecca L., Birnbaum Howard G., Morley Melissa A., Sisitsky Tamar, Greenberg Paul E., Claxton Ami J. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003 Jun;30(6):1318–1325. [PubMed] [Google Scholar]
  10. Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., van der Tempel H., van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–984. [PubMed] [Google Scholar]
  11. Van Tubergen Astrid, Boonen Annelies, Landewé Robert, Rutten-Van Mölken Maureen, Van Der Heijde Désirée, Hidding Alita, Van Der Linden Sjef. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2002 Oct 15;47(5):459–467. doi: 10.1002/art.10658. [DOI] [PubMed] [Google Scholar]
  12. Ward Michael M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002 Jan;46(1):223–231. doi: 10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  13. Webster B. S., Snook S. H. The cost of compensable low back pain. J Occup Med. 1990 Jan;32(1):13–15. doi: 10.1097/00043764-199001000-00007. [DOI] [PubMed] [Google Scholar]
  14. White K. P., Speechley M., Harth M., Ostbye T. The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol. 1999 Apr;26(4):885–889. [PubMed] [Google Scholar]
  15. Wolfe F., Anderson J., Harkness D., Bennett R. M., Caro X. J., Goldenberg D. L., Russell I. J., Yunus M. B. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997 Sep;40(9):1560–1570. doi: 10.1002/art.1780400904. [DOI] [PubMed] [Google Scholar]
  16. van der Linden S. M., Valkenburg H. A., de Jongh B. M., Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984 Mar;27(3):241–249. doi: 10.1002/art.1780270301. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES